Prior to being appointed CEO and Managing Director, Steven Yatomi-Clarke was a Non-Executive Director of Prescient Therapeutics.
Mr Yatomi-Clarke has a distinguished career in the Australian capital markets with a particular focus on the life sciences sector, where he previously held a position as a Director in Corporate Finance at Patersons Securities. During this time, he played a leading role as both a corporate advisor and fund raiser to many biotechnology companies and was consistently one of the country’s most prolific and successful healthcare bankers, involved in primary and secondary offerings, corporate advisory and M&A assignments for medical device and pharmaceutical companies. His ability to identify promising scientific opportunities, especially amidst unpredictable capital markets, saw Mr Yatomi-Clarke’s transactions consistently yield remarkable returns for investors.
Educated at the University of Melbourne, where he earned a Bachelor of Science with an Honours Degree in Biochemistry and Molecular Biology, and a Bachelor Commerce majoring in Economics, he has the rare distinction of readily bridging the divide between science and commerce.
Mr Yatomi-Clarke has also been a long-standing collaborator on immuno-oncology clinical studies in the US and Australia.